Prostate cancer is the most common cancer among men, and its prognosis is often favorable. As a result, a large number of patients remain under PSA follow-up for many years, typically with testing twice a year during the initial years. Traditionally, reviewing the required laboratory results has involved a significant amount of work by urologists.
Forsante PSA generates annual savings of hundreds of thousands of euros for healthcare organizations.
Evidence from studies on Forsante PSA follow-up* shows that automated PSA monitoring delivers savings of €100–245 per PSA control.
In automated PSA follow-up: – Forsante reminds patients of upcoming laboratory visits – PSA values are automatically interpreted according to predefined criteria – The treating unit is alerted only in cases of abnormal results or if the patient fails to attend laboratory tests despite reminders
What does this mean in practice?
In a mid-sized Finnish wellbeing services county with approximately 250,000 inhabitants, there are around 1,500 prostate cancer patients under PSA follow-up. Without automated monitoring, approximately €180,000–441,000 per year is lost (so-called cost of inaction). Through automation, these resources can be redirected to other impactful clinical work.
This represents permanent, structural impact.
Forsante PSA – automation of prostate cancer follow-up – Frees up physicians’ and nurses’ time for patients who genuinely need direct contact – Reduces administrative burden – Improves patient safety and quality of follow-up – Enables EAU guideline–compliant follow-up using criteria tailored to different patient groups
Forsante PSA is a CE-marked medical device that combines clinically validated automation with a high level of patient safety.
* The impact assessment is based on a peer-reviewed study: Bergroth R., Matikainen M. & Rannikko A. (2021). Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up, European Urology Open Science. The example is based on a Finnish wellbeing services county with 250,000 inhabitants and an estimated 1,500 patients under PSA follow-up.
